MicroRNA-552 Expression in Colorectal Cancer and Its Clinicopathological Significance

Overview

Journal J Pathol Transl Med

Specialty Biomedical Engineering

Date 2021 Feb 18

PMID 33596633

Citations 2

Authors

Joon Im

Soo Kyung Nam

Hye Seung Lee

Affiliations

Soon will be listed here.

Abstract

Background: MicroRNA-552 (miR-552) has been reported to correlate with the development and progression of various cancers, including colorectal cancer (CRC). This study aimed to investigate miR-552 expression in cancer tissue samples compared to normal mucosal tissue and its role as a diagnostic or prognostic marker in CRC patients.

Methods: Normal mucosal tissues and primary cancer tissues from 80 surgically resected CRC specimens were used. Quantitative real-time polymerase chain reaction was performed for miR-552 and U6 small nuclear RNA to analyze miR-552 expression and its clinicopathological significance. Immunohistochemistry for p53 and phosphatase and tension homolog (PTEN) was performed to evaluate their association with miR-552 expression.

Results: miR-552 expression was significantly higher in primary cancer tissues compared to normal mucosal tissues (p<.001). The expression level of miR552 was inversely correlated with that of PTEN (p=.068) and p53 (p=.004). Survival analysis showed that high miR-552 expression was associated with worse prognosis but this was not statistically significant (p=.255). However, patients with CRC having high miR-552 expression and loss of PTEN expression had significantly worse prognosis than others (p=.029).

Conclusions: Our results suggest that high miR-552 expression might be a potential diagnostic biomarker for CRC, and its combined analysis with PTEN expression can possibly be used as a prognostic marker.

Citing Articles

Blood miRNAs miR-549a, miR-552, and miR-592 serve as potential disease-specific panels to diagnose colorectal cancer.

Akbar S, Mashreghi S, Kalani M, Valanik A, Ahmadi F, Aalikhani M Heliyon. 2024; 10(7):e28492.

PMID: 38571665 PMC: 10988015. DOI: 10.1016/j.heliyon.2024.e28492.

Integration of TE Induces Cancer Specific Alternative Splicing Events.

Kim W, Park E, Lee Y, Bae W, Lee D, Kim H Int J Mol Sci. 2022; 23(18).

PMID: 36142830 PMC: 9502224. DOI: 10.3390/ijms231810918.

References

Qu W, Wen X, Su K, Gou W . MiR-552 promotes the proliferation, migration and EMT of hepatocellular carcinoma cells by inhibiting AJAP1 expression. J Cell Mol Med. 2019; 23(2):1541-1552. PMC: 6349347. DOI: 10.1111/jcmm.14062. View

Cao J, Yan X, Liu T, Han X, Yu J, Liu S . MicroRNA-552 promotes tumor cell proliferation and migration by directly targeting DACH1 via the Wnt/β-catenin signaling pathway in colorectal cancer. Oncol Lett. 2017; 14(3):3795-3802. PMC: 5588050. DOI: 10.3892/ol.2017.6600. View

Xia Z, Wang L, Yu T, Zhong W, Lian G, Wu D . MiR-5000-3p, miR-5009-3P and miR-552: potential microRNA biomarkers of side population cells in colon cancer. Oncol Rep. 2014; 32(2):589-96. DOI: 10.3892/or.2014.3232. View

Kim H, Lim N, Jang S, Lee G . miR-592 and miR-552 can distinguish between primary lung adenocarcinoma and colorectal cancer metastases in the lung. Anticancer Res. 2014; 34(5):2297-302. View

Somasundaram K . Tumor suppressor p53: regulation and function. Front Biosci. 2000; 5:D424-37. DOI: 10.2741/somasund. View

Lee R, Feinbaum R, Ambros V . The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75(5):843-54. DOI: 10.1016/0092-8674(93)90529-y. View

Calin G, Croce C . MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006; 66(15):7390-4. DOI: 10.1158/0008-5472.CAN-06-0800. View

Chen T, Lei S, Zeng Z, Zhang J, Xue Y, Sun Y . Linc00261 inhibits metastasis and the WNT signaling pathway of pancreatic cancer by regulating a miR‑552‑5p/FOXO3 axis. Oncol Rep. 2020; 43(3):930-942. PMC: 7041108. DOI: 10.3892/or.2020.7480. View

Tong F, Ying Y, Pan H, Zhao W, Li H, Zhan X . MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC). Bosn J Basic Med Sci. 2018; 18(3):252-259. PMC: 6087559. DOI: 10.17305/bjbms.2018.2376. View

10.

Kwak B, Kim D, Kim T, Kim H, Kim S . MicroRNA-552 links Wnt signaling to p53 tumor suppressor in colorectal cancer. Int J Oncol. 2018; 53(4):1800-1808. DOI: 10.3892/ijo.2018.4505. View

11.

Jeffrey S . Cancer biomarker profiling with microRNAs. Nat Biotechnol. 2008; 26(4):400-1. DOI: 10.1038/nbt0408-400. View

12.

Han T, Zhang Y, Yang X, Han L, Li H, Chen T . miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance. Mol Ther Nucleic Acids. 2020; 19:1073-1085. PMC: 7015836. DOI: 10.1016/j.omtn.2019.12.043. View

13.

Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E . Combinatorial microRNA target predictions. Nat Genet. 2005; 37(5):495-500. DOI: 10.1038/ng1536. View

14.

Maehama T, Dixon J . The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 273(22):13375-8. DOI: 10.1074/jbc.273.22.13375. View

15.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

16.

Ji J, Yamashita T, Wang X . Wnt/beta-catenin signaling activates microRNA-181 expression in hepatocellular carcinoma. Cell Biosci. 2011; 1(1):4. PMC: 3116242. DOI: 10.1186/2045-3701-1-4. View

17.

Li C, Wang Z, Chen S, Zhang J, Qu K, Liu C . MicroRNA-552 promotes hepatocellular carcinoma progression by downregulating WIF1. Int J Mol Med. 2018; 42(6):3309-3317. PMC: 6202085. DOI: 10.3892/ijmm.2018.3882. View

18.

Calin G, Sevignani C, Dumitru C, Hyslop T, Noch E, Yendamuri S . Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004; 101(9):2999-3004. PMC: 365734. DOI: 10.1073/pnas.0307323101. View

19.

Weiser M . AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018; 25(6):1454-1455. DOI: 10.1245/s10434-018-6462-1. View

20.

Vivanco I, Sawyers C . The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7):489-501. DOI: 10.1038/nrc839. View